Literature DB >> 8279537

Effects of recombinant human IGF-I on glucose and leucine kinetics in men.

D Elahi1, M McAloon-Dyke, N K Fukagawa, A L Sclater, G A Wong, R P Shannon, K L Minaker, J M Miles, A H Rubenstein, C J Vandepol.   

Abstract

To examine the effects of recombinant human (rh) insulin-like growth factor I (IGF-I), insulin, and saline on metabolic parameters, we studied 20 young nonobese healthy men. Euglycemic clamps with 240-min IGF-I infusions at two doses (49 and 33 pmol.kg-1 x min-1, n = 8 and 12 subjects) were performed and compared with hyperinsulinemic-euglycemic clamps (2.25 pmol.kg-1 x min-1, n = 9). Leucine and glucose kinetics were examined with L-[1-13C]leucine and [3-3H]glucose. Glucose rate of appearance (Ra) declined equivalently in the 49 pmol.kg-1.min-1 IGF-I and insulin clamps but remained at basal levels during the 33 pmol.kg-1 x min-1 IGF-I infusions. In contrast, Rd of glucose was increased by 176% in the 49 pmol.kg-1 x min-1 IGF-I and 78% in the 33 pmol.kg-1 x min-1 IGF-I infusions. Furthermore, to prevent hypoglycemia after the termination of both rhIGF-I infusions, it was necessary to infuse glucose for an additional 2-20 h. Ra of leucine was suppressed significantly by both IGF-I and insulin, whereas leucine oxidation was not affected by either hormone. Therefore, the rate of disappearance of leucine expressed as the difference between Ra and oxidation rates was significantly reduced in all clamps. In addition, IGF-I significantly suppressed beta-cell secretion without affecting the other glucoregulatory hormones. In contrast to insulin, IGF-I had no apparent effect on lipolysis, as measured by changes in nonesterified fatty acids.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8279537     DOI: 10.1152/ajpendo.1993.265.6.E831

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  7 in total

Review 1.  The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes.

Authors:  Swapnil N Rajpathak; Marc J Gunter; Judith Wylie-Rosett; Gloria Y F Ho; Robert C Kaplan; Radhika Muzumdar; Thomas E Rohan; Howard D Strickler
Journal:  Diabetes Metab Res Rev       Date:  2009-01       Impact factor: 4.876

2.  Comparison of the effects of growth hormone and insulin-like growth factor I on substrate oxidation and on insulin sensitivity in growth hormone-deficient humans.

Authors:  M A Hussain; O Schmitz; A Mengel; Y Glatz; J S Christiansen; J Zapf; E R Froesch
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

3.  Comparison of the effects of human recombinant insulin-like growth factor I and insulin on plasma amino acid concentrations and leucine kinetics in humans.

Authors:  M Giordano; P Castellino; C A Carroll; R A DeFronzo
Journal:  Diabetologia       Date:  1995-06       Impact factor: 10.122

4.  Insulin and insulin-like growth factor-I enhance human skeletal muscle protein anabolism during hyperaminoacidemia by different mechanisms.

Authors:  D A Fryburg; L A Jahn; S A Hill; D M Oliveras; E J Barrett
Journal:  J Clin Invest       Date:  1995-10       Impact factor: 14.808

5.  Insulin-like growth factor 1, glycation and bone fragility: implications for fracture resistance of bone.

Authors:  Grażyna E Sroga; Ping-Cheng Wu; Deepak Vashishth
Journal:  PLoS One       Date:  2015-01-28       Impact factor: 3.240

Review 6.  Insulin-like growth factor-1 deficiency and metabolic syndrome.

Authors:  G A Aguirre; J Rodríguez De Ita; R G de la Garza; I Castilla-Cortazar
Journal:  J Transl Med       Date:  2016-01-06       Impact factor: 5.531

7.  Comparative Proteomic Analysis of Two Differently Extracted Coptis chinensis in the Treatment of Type 2 Diabetic Rats.

Authors:  Xin Qiu; Xinyu Wei; Hongwei Guan; Hao Su; Jing Gong; Ke Fang; Xin Zou; Hui Dong; Lijun Xu; Fuer Lu
Journal:  Evid Based Complement Alternat Med       Date:  2018-09-13       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.